Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho

Mizuho analyst Graig Suvannavejh raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $42.00 (from $30.00) while maintaining a Outperform rating.

The analyst comments "We raise our PT 40% higher to $42 (vs. $30 prior), following positive results from the highly anticipated, P3 LUCIDITY study for lead asset avexitide in post-bariatric hypoglycemia/PBH. In our view, today's highly successful P3 outcome marks a dramatic and complete turnaround and rebirth for the company, which fell from investors' grace after negative P3 PHOENIX study data were reported in March 2024 for its former ALS asset Relyvrio. With positive P3 data in hand, we look to a US regulatory filing by YE26, and assuming a priority review, a product launch (and return to revenue) in 2H27. Indeed, investor debates are likely to persist (re: on avexitide's potential label and market potential); that said, given a significant de-risking event, and on our new PT, ~30% upside on the current $32-33 intra-day level, we reiterate our OP rating on AMLX, a top 2026 pick."

You May Also Be Interested In

• Guggenheim Downgrades Alumis Inc (ALMS) to Neutral
• ONEOK Inc (OKE) PT Raised to $104 at Truist Securities
• Dell (DELL) PT Raised to $505 at Truist Securities